LCM
DAWN

Legato Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Legato Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,027
Closed -$786K – 584
2024
Q4 		$786K Sell
62,027
-1,140
-2% -$15.9K 0.1% 343
2024
Q3 		$880K Buy
+63,167
New +$901K 0.11% 335
2024
Q2 		– Sell
-32,029
Closed -$529K – 576
2024
Q1 		$529K Sell
32,029
-9,889
-24% -$148K 0.06% 429
2023
Q4 		$612K Buy
41,918
+5,242
+14% +$63.5K 0.08% 374
2023
Q3 		$450K Sell
36,676
-7,012
-16% -$91.5K 0.07% 415
2023
Q2 		$522K Buy
43,688
+13,696
+46% +$179K 0.07% 413
2023
Q1 		$401K Buy
29,992
+6,218
+26% +$121K 0.07% 387
2022
Q4 		$512K Buy
+23,774
New +$488K 0.1% 348

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

Legato Capital Management's DAWN Position: Q1 2025 in Review

Legato Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 62,027 shares — an estimated $786K sold.

Legato Capital Management first reported a position in DAWN in Q4 2022 and held it in 8 quarters. The position peaked at $880K in Q3 2024. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

  • Legato Capital Management reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Legato Capital Management sold 62,027 Day One Biopharmaceuticals shares in Q1 2025, an estimated $786K.
  • Legato Capital Management first reported a position in Day One Biopharmaceuticals in Q4 2022 and held it in 8 quarters.
  • Legato Capital Management's Day One Biopharmaceuticals position peaked at $880K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on Legato Capital Management's 13F filing for Q1 2025, filed 6 May 2025.